SERB is a growing pharmaceutical company and a dedicated ally to healthcare providers treating patients with critical conditions, focusing on emergency care and rare diseases. For over 30 years we have made treating these complex and life-threatening conditions possible; supporting clinicians, healthcare systems and governments while offering hope to patients and their families. SERB began in the 1950s as Société d’Études et de Recherches Biologiques (Company for Biologic Study and Research). Today SERB has the broadest antidote portfolio in the world, including medical countermeasures for chemical, biological, radiological and nuclear (CBRN) risks. As a fully integrated company, we have the experience and capabilities to acquire, develop, and manufacture our medicines to the highest standards, and make them available worldwide through our secure supply chain. Improving patients’ quality of life and offering hope is what motivates and inspires us. SERB operates in the US as BTG Pharmaceuticals.